AICAR

AICAR activates the same AMPK pathway that physical exercise activates. In laboratory conditions this produced endurance improvements in sedentary animals who did no exercise. In practice, for human users who do exercise, it amplifies the AMPK signal beyond what training alone achieves — more mitochondrial adaptation per unit of training stimulus.

AICAR is banned by WADA in competitive sports due to its endurance-enhancing mechanism. Users in competitive sport should verify their governing body's substance policies. For non-competitive research and longevity use, it is a legal research compound in most jurisdictions.

Both activate AMPK but through different mechanisms. Metformin inhibits Complex I of the mitochondrial electron transport chain, indirectly raising AMP:ATP ratio. AICAR directly provides a ZMP that allosterically activates AMPK more directly. AICAR produces stronger AMPK activation at equivalent doses, with more pronounced effects on mitochondrial biogenesis and endurance.

The original research showed benefit in sedentary animals. In sedentary humans, AICAR would produce metabolic improvements (insulin sensitivity, fat oxidation) without exercise. However, AMPK activation is synergistic with exercise — the benefits of combining both substantially exceed either alone. Use alongside training for best results.

AICAR is generally well tolerated in short-term research. The primary reported concern at high doses is lactic acidosis in cell models (AICAR can affect mitochondrial respiration at very high concentrations), but this has not been clinically observed at human research doses. Monitoring lactate during early use at higher doses is a reasonable precaution.

AICAR pairs well with MOTS-c (both activate AMPK via different mechanisms, providing additive stimulation), with SS-31 (which improves the mitochondria that AICAR builds), and with 5-Amino-1MQ (NNMT inhibition addresses complementary NAD+/fat oxidation pathways). Together they represent a comprehensive metabolic optimisation approach.